Driven by chemistry but increasingly guided by pharmacology and the clinical sciences,
drug research has contributed more to the progress of medicine during the past century than …

Genetic polymorphisms in drug-metabolizing enzymes, transporters, receptors, and other
drug targets have been linked to interindividual differences in the efficacy and toxicity of …

The cytochrome p450 enzyme, CYP2D6, metabolises approximately 20% of marketed
drugs. CYP2D6 multiple variants are associated with altered enzyme activities. Genoty** …

Background. Adherence is a factor in the outcome of medical treatment, but the strength and
moderators of the adherence-outcome association have not been systematically assessed …

It is well recognized that different patients respond in different ways to the same medication.
These differences are often greater among members of a population than they are within the …

Cholesteryl ester transfer protein (CETP) promotes the transfer of cholesteryl esters from
antiatherogenic HDLs to proatherogenic apolipoprotein B (apoB)–containing lipoproteins …

Genetic factors contribute importantly to the risk of coronary artery disease (CAD), and in the
past decade, there has been major progress in this area. The tools applied include genome …

The history of biology was forever altered a decade ago by the bold decision to launch a
research program that would characterize in ultimate detail the complete set of genetic …

Currently, five different statins (simvastatin, pravastatin, lovastatin, fluvastatin, and
atorvastatin) are approved for treatment of hypercholesterolemia in humans and two new …

It is well known that cardiovascular diseases have a substantial heritable component, but the
precise genetic variants responsible for this familial tendency have been hard to uncover. In …